Cellular Biomedicine Group Inc. announced that it has entered into a global collaboration and licensing agreement with Janssen Biotech Inc. to develop and commercialize Non-Hodgkin lymphoma drugs. Cellular Biomedicine will receive $245 million in upfront payments and milestone payments upon certain clinical development and sales achievements. Rockville, Maryland-based Cellular Biomedicine was advised by a Davis Polk & Wardwell team that included partner David R. Bauer. Counsel information for Janssen Biotech, which is based in Montgomery County, Pennsylvania, was not immediately available.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.